Chataway, Jeremy;
Williams, Thomas;
Li, Vivien;
Marrie, Ruth Ann;
Ontaneda, Daniel;
Fox, Robert J;
(2024)
Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges.
The Lancet Neurology
, 23
(3)
pp. 277-301.
10.1016/S1474-4422(24)00027-9.
Preview |
Text
Chataway_zFigures_v3.1.pdf Download (174kB) | Preview |
Preview |
Text
Chataway_zAppendixTables_referenced_2024_final.pdf Download (503kB) | Preview |
Preview |
Text
Chataway_23tln0301_Chataway_Tables for Prod.pdf Download (431kB) | Preview |
Preview |
Text
Chataway_23tln0301_Chataway_Text for Prod.pdf Download (442kB) | Preview |
Abstract
Despite the success of disease-modifying treatments in relapsing multiple sclerosis, for many individuals living with multiple sclerosis, progressive disability continues to accrue. How to interrupt the complex pathological processes underlying progression remains a daunting and ongoing challenge. Since 2014, several immunomodulatory approaches that have modest but clinically meaningful effects have been approved for the management of progressive multiple sclerosis, primarily for people who have active inflammatory disease. The approval of these drugs required large phase 3 trials that were sufficiently powered to detect meaningful effects on disability. New classes of drug, such as Bruton tyrosine-kinase inhibitors, are coming to the end of their trial stages, several candidate neuroprotective compounds have been successful in phase 2 trials, and innovative approaches to remyelination are now also being explored in clinical trials. Work continues to define intermediate outcomes that can provide results in phase 2 trials more quickly than disability measures, and more efficient trial designs, such as multi-arm multi-stage and futility approaches, are increasingly being used. Collaborations between patient organisations, pharmaceutical companies, and academic researchers will be crucial to ensure that future trials maintain this momentum and generate results that are relevant for people living with progressive multiple sclerosis.
| Type: | Article |
|---|---|
| Title: | Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/S1474-4422(24)00027-9 |
| Publisher version: | http://dx.doi.org/10.1016/s1474-4422(24)00027-9 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10192238 |
Loading...
Loading...Loading...Loading...Archive Staff Only
 |
View Item |
